Renal disease after mitomycin C therapy.
Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5-fluorouracil (5-FU) had renal impairment 6-11 months from the beginning of MMC therapy. Two clinical entities were recognized: an acute fulminating renal failure that was rapidly fatal and a chronic slowly progressive renal impairment. The first entity showed a microangiopathic hemolytic profile with anemia, thrombocytopenia, and erythrocyte fragmentation. Light microscopy and electron microscopy examination of the kidney revealed a primary vascular disease with musculomucoid intimal hyperplasia of arteries and rare fibrin thrombi in arterioles. Interstitial fibrosis, tubular atrophy, and widespread glomerular necrosis were also seen. The disease was ultimately fatal within three to four weeks. The second entity showed a chronic course of renal failure with similar pathologic findings but less pronounced, and a microangiopathic hemolysis was absent. The course in the second group was ultimately fatal between three to eight months.
D058186:Acute Kidney Injury / Q000139:chemically induced; D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001794:Blood Pressure; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D005472:Fluorouracil / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000098:blood supply* / Q000473:pathology / Q000648:ultrastructure; D007674:Kidney Diseases / Q000139:chemically induced* / Q000401:mortality / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000139:chemically induced; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use*
D008937:Mitomycins; D016685:Mitomycin; D003404:Creatinine; D005472:Fluorouracil